Register for our free email digests:
Regulation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The Factory Floor: Suanfarma Expands API Capacity With Sandoz Deal In Italy
Suanfarma acquires an API manufacturing facility in Italy to accelerate its growth in Europe, while CapsCanada relocates its headquarters as part of its growth strategy. Meanwhile, Glenmark, Aurobindo and Cipla struggle with quality issues.
AAM Slams California Pay-For-Delay Ban
US off-patent industry association the AAM has blasted as unconstitutional a groundbreaking California law banning so-called ‘pay-for-delay’ deals under which brand companies pay rivals to keep generics off the market.
FDA Fights Problems With Pre-ANDA Meeting Requests
More meeting requests are being denied because the sponsor's pre-meeting package was incomplete, the agency said.
Nitrosamine Issue Presages Paradigm Shift In Quality
The detection of cancer-causing impurities in drugs with well-established safety profiles may force regulators across the globe to revise their approach for evaluating quality.
First UK Serious Shortage Protocol Issued For Fluoxetine
The first Serious Shortage Protocol has been issued by the DHSC to tackle supply disruptions for fluoxetine capsules. The protocol came into effect on 3 October 2019 and will expire at the end of the month.
US Biosimilar Fee Collections Fall Short
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.